BMNR Price Analysis: The Key Level to Watch
1 extracted signal · 0 resolved · 1 still active
MCO Global US Independent analyst profile- Source published
- 20 Sept 2026, 20:06 UTC
- Recorded by Tahlil Plus
- 20 Sept 2026, 23:06 UTC
AI-generated source summary
The analysis of BMNR presents a bullish outlook based on a potential five-wave impulse pattern. The current price is observed at $25.84. The primary target is set at the 50% Fibonacci retracement level of $45.79, which aligns with the upper boundary of a significant resistance zone. The fail bound is identified at $21.64, corresponding to the 50% retracement of the preceding three-wave corrective move. A break below this level would invalidate the bullish five-wave count, suggesting a deeper correction or a change in trend. The analysis suggests that the price has completed a three-wave decline and is now in an upward corrective phase, aiming for higher highs. The timeframe for this analysis is the 4-hour chart, indicating a medium-term trading perspective. The immediate resistance is noted around $26.82, and a clear break above this level is anticipated to confirm the continuation of the bullish trend towards the primary target. Further price action will be monitored to validate the wave count and the projected targets.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
MCO Global US
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.